ONCOmmunity

Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.

By: Eleftherios Spartalis, Dimitrios I Athanasiadis, Dimosthenis Chrysikos, Michael Spartalis, Georgios Boutzios, Dimitrios Schizas, Nikolaos Garmpis, Christos Damaskos, Stavroula A Paschou, Argyrios Ioannidis, Gerasimos Tsourouflis, Dimitrios Dimitroulis, Nikolaos I Nikiteas

Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, National and Kapodistrian University of Athens, Athens, Greece eleftherios.spartalis@gmail.com.
2019-01-25; doi: 10.21873/anticanres.13220

Abstract

Background/aim

Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, remaining generally incurable. Histone deacetylase (HDAC) seems to play a role in regulating transcription of genes involved in ATC, making HDAC inhibitors (HDACI) promising anticancer drugs for ATC. The purpose of this review was to evaluate the role of HDACIs in ATC treatment and describe the latest trends of current research on this field.

Materials

This literature review was performed using the MEDLINE database. The keywords/phrases were; thyroid cancer, anaplastic, HDAC, histone, deacetylase*, HDACI.

Results

Compounds, such as SuberoylAnilide Hydroxamic Acid, valproic acid, sodium butyrate, butyrate, phenylbutyrate, trichostatin A, AB1-13, panobinostat or LBH589, belinostat, MS-275, depsipeptide, CUDC101, CUDC907, N-Hydroxy-7-(2-naphthylthio)-Hepanomide (HNHA), and PXD101 have shown promising antitumor effects against ATC.

Conclusion

HDACIs represent a promising therapy for ATC management, both as monotherapy and in combination with other anticancer drugs.